BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 17303489)

  • 21. Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial.
    Guang-Sheng F; Mei-Lu B; Li-Nan C; Xiao-Ming C; Zi-Rong H; Zi-Yan H; Xiao-Ping J; Jian L; Shu-Ying W; Cheng-Liang X; Zheng-Ai X; Tian-Fu Y
    Clin Drug Investig; 2010; 30(6):387-96. PubMed ID: 20201608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of gender and body composition on hydration and body water spaces.
    Ritz P; Vol S; Berrut G; Tack I; Arnaud MJ; Tichet J
    Clin Nutr; 2008 Oct; 27(5):740-6. PubMed ID: 18774628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone.
    Oelkers W
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():17-24. PubMed ID: 11246598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives.
    Loughlin J; Seeger JD; Eng PM; Foegh M; Clifford CR; Cutone J; Walker AM
    Contraception; 2008 Nov; 78(5):377-83. PubMed ID: 18929734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception.
    Borges LE; Andrade RP; Aldrighi JM; Guazelli C; Yazlle ME; Isaia CF; Petracco A; Peixoto FC; Camargos AF
    Contraception; 2006 Dec; 74(6):446-50. PubMed ID: 17157100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women.
    Blode H; Foidart JM; Heithecker R
    Eur J Contracept Reprod Health Care; 2001 Sep; 6(3):167-71. PubMed ID: 11763981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective study on the cytological aspects of the nasal respiratory epithelium in premenopausal women taking 30 mcg ethinylestradiol and 3 mg drospirenone oral contraceptive.
    Caruso S; Serra A; Grillo C; Agnello C; Di Mari L; Cianci A
    Contraception; 2008 May; 77(5):344-9. PubMed ID: 18402850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen.
    Klipping C; Duijkers I; Trummer D; Marr J
    Contraception; 2008 Jul; 78(1):16-25. PubMed ID: 18555813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects.
    Foidart JM
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():25-33. PubMed ID: 11246599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters.
    Douxfils J; Klipping C; Duijkers I; Kinet V; Mawet M; Maillard C; Jost M; Rosing J; Foidart JM
    Contraception; 2020 Dec; 102(6):396-402. PubMed ID: 32956694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of a continuous regimen of drospirenone 3 mg/ethinylestradiol 30 microg on Cox-2 and Ki-67 expression in the endometrium.
    Maia H; Casoy J; Athayde C; Valente Filho J; Coutinho EM
    Eur J Contracept Reprod Health Care; 2010 Feb; 15(1):35-40. PubMed ID: 20063991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Body water distribution in severe obesity and its assessment from eight-polar bioelectrical impedance analysis.
    Sartorio A; Malavolti M; Agosti F; Marinone PG; Caiti O; Battistini N; Bedogni G
    Eur J Clin Nutr; 2005 Feb; 59(2):155-60. PubMed ID: 15340370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination.
    Aydin K; Cinar N; Aksoy DY; Bozdag G; Yildiz BO
    Contraception; 2013 Mar; 87(3):358-62. PubMed ID: 22898361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism.
    Klipping C; Marr J
    Contraception; 2005 Jun; 71(6):409-16. PubMed ID: 15914128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive.
    Keam SJ; Wagstaff AJ
    Treat Endocrinol; 2003; 2(1):49-70. PubMed ID: 15871554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes.
    Mona Eng P; Seeger JD; Loughlin J; Oh K; Walker AM
    Contraception; 2007 Feb; 75(2):101-7. PubMed ID: 17241838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 microg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment.
    Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
    J Drugs Dermatol; 2009 Sep; 8(9):837-44. PubMed ID: 19746676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone.
    Blode H; Schürmann R; Benda N
    Contraception; 2008 Mar; 77(3):171-6. PubMed ID: 18279686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms.
    Apter D; Borsos A; Baumgärtner W; Melis GB; Vexiau-Robert D; Colligs-Hakert A; Palmer M; Kelly S
    Eur J Contracept Reprod Health Care; 2003 Mar; 8(1):37-51. PubMed ID: 12725674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective study on sexual behavior of women using 30 microg ethinylestradiol and 3 mg drospirenone oral contraceptive.
    Caruso S; Agnello C; Intelisano G; Farina M; Di Mari L; Sparacino L; Cianci A
    Contraception; 2005 Jul; 72(1):19-23. PubMed ID: 15964287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.